<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Apolipoprotein E and Alpha-1-Antichymotrypsin Polymorphisms in Sporadic Inclusion Body Myositis</title>
			</titleStmt>
			<publicationStmt>
				<publisher>S. Karger AG</publisher>
				<availability status="unknown"><p>Copyright S. Karger AG</p>
				</availability>
				<date type="published" when="2004-05-17">May 17, 2004</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">G</forename><surname>Gossrau</surname></persName>
							<email>ggossrau@uni-bonn.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Institute of Reconstructive Neurobiology</orgName>
								<orgName type="institution">University of Bonn Medical Center</orgName>
								<address>
									<settlement>Bonn</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Gestrich</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Koch</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Biomathematics</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Wunderlich</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Medical Clinic II</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Technical University Dresden</orgName>
								<address>
									<settlement>Dresden</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schröder</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">University of Aachen</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Schroeder</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University of Bonn</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Reichmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Lampe</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Schering AG</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Institute of Reconstructive Neurobiology</orgName>
								<orgName type="institution">University of Bonn Medical Center</orgName>
								<address>
									<addrLine>Sigmund-Freud-Strasse 25</addrLine>
									<postCode>DE-53105</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">University of Illinois</orgName>
								<address>
									<addrLine>130.126.143</addrLine>
									<postCode>77 -3/9/2023</postCode>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">University of Illinois</orgName>
								<address>
									<addrLine>130.126.143</addrLine>
									<postCode>77 -3/9/2023</postCode>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution">University of Illinois</orgName>
								<address>
									<addrLine>130.126.143</addrLine>
									<postCode>77 -3/9/2023</postCode>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="institution">University of Illinois</orgName>
								<address>
									<addrLine>130.126.143</addrLine>
									<postCode>77 -3/9/2023</postCode>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Apolipoprotein E and Alpha-1-Antichymotrypsin Polymorphisms in Sporadic Inclusion Body Myositis</title>
					</analytic>
					<monogr>
						<title level="j" type="main">European Neurology</title>
						<title level="j" type="abbrev">Eur Neurol</title>
						<idno type="ISSN">0014-3022</idno>
						<idno type="eISSN">1421-9913</idno>
						<imprint>
							<publisher>S. Karger AG</publisher>
							<biblScope unit="volume">51</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page" from="215" to="220"/>
							<date type="published" when="2004-05-17">May 17, 2004</date>
						</imprint>
					</monogr>
					<idno type="MD5">011F4BC03E12AB03939830FCDF901F58</idno>
					<idno type="DOI">10.1159/000078488</idno>
					<note type="submission">Received: October 21, 2003 Accepted: February 10, 2004</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Sporadic inclusion body myositis (s-IBM) is a progressive muscle disease of unknown aetiology. Characteristically, intracellular amyloid deposits are detectable, including ß-amyloid precursor protein, phosphorylated tau, • 1 -antichymotrypsin (• 1 -ACT) and apolipoprotein E (ApoE). Polymorphisms and mutations of the encoding genes have been identified in a variety of neurodegenerative diseases including Alzheimer's disease (AD). Beside other factors, polymorphisms may lead to protein accumulation in both diseases. In particular, polymorphisms within the ApoE and • 1 -ACT gene have been implicated in the aetiology of AD and s-IBM. We analysed ApoE and • 1 -ACT gene polymorphisms in 35 s-IBM patients. We could not identify any statistical significant correlation between distinct ApoE and • 1 -ACT genotypes and the risk of developing s-IBM. Additionally, ApoE and • 1 -ACT genotypes seem not to influence the onset age of s-IBM. A combination of different • 1 -ACT and ApoE genotypes appears not to enhance the risk of develop-ing s-IBM. Therefore, allelic variations of • 1 -ACT and ApoE are unlikely to be genetic key factors in the aetiology of s-IBM.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Sporadic inclusion body myositis (s-IBM) is recognized as the most common muscle disease that starts after the age of 50. s-IBM is of unknown cause and unconfirmed pathogenesis <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Microscopically, muscle biopsies are characterized by inflammation, 'rimmed vacuoles' and characteristic cytoplasmic and nuclear filamentous inclusions. Ultrastructurally, 15-to 18-nm tubulofilaments are present <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Clinically, patients suffer from a slowly progressive inflammatory myopathy, which finally leads to severe disability. The muscle weakness is distal and proximal in the lower and upper limbs. The forearm muscles and the musculus quadriceps femoris are typically affected. Dysphagia is a common clinical feature whereas respiratory muscle weakness can be found occasionally <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</p><p>An astounding aspect of the s-IBM muscle fibre histological phenotype is its similarity to that of the Alzhei-Gossrau/Gestrich/Koch/Wunderlich/ Schröder/Schroeder/Reichmann/Lampe mer's disease (AD) brain <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>. Several proteins found in amyloid plaques typical of AD accumulate in s-IBM muscle fibres, including apolipoprotein E (ApoE), • 1 -antichymotrypsin (• 1 -ACT), prion protein, hyperphosphorylated tau, presenilin 1, ubiquitin, ß-amyloid (Aß) and ß-amyloid precursor protein <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>. Moreover, tubulofilaments found in s-IBM resemble AD neurofibrillary tangles <ref type="bibr" target="#b9">[10]</ref>. These points questioned the analogies in degenerative processes between AD and s-IBM <ref type="bibr" target="#b5">[6]</ref>.</p><p>ApoE is physically associated with extracellular senile plaques and intracellular neurofibrillary tangles in AD. ApoE as a plasma protein is produced and secreted in the central nervous system by astrocytes <ref type="bibr" target="#b10">[11]</ref>. It is involved in the transport of cholesterol, which may in part explain the link between certain ApoE alleles and the risk of developing AD. ApoE is implicated in the growth and repair of the nervous system during development or after injury <ref type="bibr" target="#b11">[12]</ref>.</p><p>So far certain polymorphisms of the ApoE may lead to functionally different gene products with unequal repair properties and interactions with molecular chaperones in the nervous system as well as in other organs.</p><p>ApoE accumulates abnormally within s-IBM muscle fibres <ref type="bibr" target="#b12">[13]</ref>. It is localized by means of light microscopy in intracellular inclusions that closely colocalize with phosphorylated tau and Aß <ref type="bibr" target="#b13">[14]</ref>. Interestingly, ApoE binds to Aß and ß-pleated-sheet amyloid produced by various proteins in vitro <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>. On the other hand, ApoE mRNA</p><p>has not yet been described in s-IBM muscle fibres. Therefore it is likely that the ApoE accumulation arises from the import of circulating protein into muscle fibres and its subsequent binding to Aß <ref type="bibr" target="#b13">[14]</ref>.</p><p>An increased frequency of the ApoE Â4 allele is associated with earlier onset of sporadic and late-onset familial AD <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>. In s-IBM patients one group demonstrated an increase in the ApoE Â4 allele frequency <ref type="bibr" target="#b20">[21]</ref>, which could not be confirmed by two different groups <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</p><p>• 1 -ACT inhibits serine proteases and belongs to the serpin superfamily. It is considered a major acute-phase protein. Further proposed functions are control of connective-tissue breakdown and cell-to-cell interactions as well as inhibition of natural killer cell activity <ref type="bibr" target="#b23">[24]</ref>. Abnormal • 1 -ACT accumulation has been described in amyloid plaques of AD brains <ref type="bibr" target="#b24">[25]</ref>. Because of the close associations with Aß, it may possibly play a role in amyloid fibril formation. As in the AD brain, • 1 -ACT closely colocalizes with Aß in s-IBM muscle <ref type="bibr" target="#b25">[26]</ref>.</p><p>In view of the morphochemical similarities between AD and s-IBM, the question of the possible relevance in terms of common pathogenic pathways in both diseases arises.</p><p>In s-IBM CD8+ cytotoxic T cells infiltrate muscle fibres <ref type="bibr" target="#b3">[4]</ref>. Since • 1 -ACT inhibits the natural killer cell activity, a defined polymorphism of this gene might modify its proposed immunomodulatory functions <ref type="bibr" target="#b23">[24]</ref>.</p><p>Certain ApoE and • 1 -ACT polymorphisms have been proposed to be susceptible markers for AD. Thus, the aim of this study was to investigate if the segregation of ApoE and • 1 -ACT in patients with s-IBM resemble the proposed aetiopathogenetic similarities in AD and s-IBM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>A total of 35 German patients (women and men) fulfilling the clinical and histological criteria for definite s-IBM were included. The mean age of the patients was 62.8 years (between 16 and 74). The results were compared with 57 healthy control subjects and formerly published results <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref>. Genomic DNA was isolated from peripheral blood lymphocytes (GenomeClean Kit, AGS GmbH, Heidelberg, Germany) according to the manufacturers' instructions. Subsequently, a part of an ApoE gene containing allelic polymorphism at codon 112 and codon 158 was amplified as previously described <ref type="bibr" target="#b29">[30]</ref>. The PCR products were CfO digested and separated on a 2% agarose gel, visualized with ethidium bromide staining (fig. <ref type="figure" target="#fig_0">1</ref>). The • 1 -ACT allelic polymorphism was determined after amplification of a 124-base-pair gene fragment using the primers CAG AGT TGA GAA TGG AGA (sense) and TTC TCC TGG GTC AGA TTC (antisense). The genomic DNA was amplified under the following conditions: denaturation, 95 °C, 1 min; annealing, 50 °C, 2 min; extension, 72 °C, 1 min. The cycle was repeated 25 times. The PCR products were digested with 5 units of the enzyme MvaI (Roche, Mannheim, Germany), for 1.5 h, at 37 °C and analyzed in an ethidium-bromide-stained 2% agarose gel (peqLab, Erlangen, Germany). Mva-digested PCR products from patients revealed the genotypes A/A, T/T and A/T at the ACT locus.</p><p>The resulting ApoE allele frequencies of s-IBM patients were compared with normal control subjects. Because certain ApoE alleles are known to influence the age at AD onset we correlated the ApoE alleles in s-IBM patients with the age of disease onset. Distinct • 1 -ACT alleles have been found to enhance the former stated ApoE effect on disease onset in AD. To see if there is a comparable effect in s-IBM, we correlated • 1 -ACT and ApoE allele expression with age at disease onset <ref type="bibr" target="#b29">[30]</ref>.</p><p>The • 1 -ACT A/A polymorphism confers to the risk of developing AD. We tested the • 1 -ACT allele segregation in s-IBM and compared it with healthy controls.</p><p>Statistical analysis was performed using the ¯2 test (p value Mantel-Haenszel corrected). This method has been shown to be a useful approach in describing differences of ApoE and • 1 -ACT allele frequencies in various populations <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref>. In the case of low filled cells, the Fisher exact test was performed for a two-tailed test of the difference.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>To sum up, we analysed 35 patients, 24 (68.5%) of whom were male, 11 (31.4%) female. Genotypes of patients and controls are shown in table 1. Table <ref type="table" target="#tab_1">2</ref> displays the comparison of own data with previously published data. The ApoE Â4 was present in 14.3% of patients and in 11.4% of control subjects (p = 0.761 in Fisher's exact test). 10% of s-IBM patients carried the ApoE Â2 allele compared to 3.5% of the control group. This small difference lacked statistical significance (p = 0.19 in Fisher's exact test). Likewise we did not find any significant differences between s-IBM patients and control subjects regarding the ApoE Â4 allelic distribution. The ApoE Â2/4 genotype was present in 2, the ApoE Â3/4 genotype in 8 and the ApoE Â4/4 genotype in none of 35 patients. No significant difference between patients and control subjects was noticeable.</p><p>The mean age at disease onset for all s-IBM patients was 54.5 years (ranging from 16 to 74). The mean age at onset was 46 years for the ApoE Â3/4 bearers and 56 years for the ApoE Â3/3 bearers. One patient with ApoE Â2/4 genotype was aged 70 when the disease started. The mean age of the 3 ApoE Â2/3 carriers was 49 years. We found that the age at disease onset was very similar in the different genotype bearers. The 1 patient carrying ApoE Â2/4 with late disease onset cannot be taken into consideration.</p><p>The ACT genotyping results for 29 patients and controls are shown in table 3. We could not find any signifi-  The mean age at disease onset was 54 years for the ACT AA bearers, 50 for the ACT AT carriers and 61 for the 5 ACT TT homozygous patients. So far, the different genotype carriers had nearly the same mean age at disease onset. We investigated whether ApoE and ACT act together to determine an individual's risk of developing s-IBM. The corresponding data are shown in table <ref type="bibr" target="#b3">4</ref>. In s-IBM patients the ACT AA genotype was associated with low frequencies of ApoE Â4 compared to the other 2 genotypes of ACT (p = 0.072 as opposed to p = 0.178 and p = 0.1) and compared to the results of ApoE-Â4-positive ACT AA carriers in the control group (p = 0.072 versus p = 0.0116).</p><p>Interestingly, the patients' ACT AA genotype was associated with higher frequencies of the ApoE Â2 allele compared to the AT and TT genotype within the patients' group (0.143 vs. 0.058 and 0) and in contrast to the controls with AA genotype (0.143 vs. 0.038). This last finding is statistically not significant. For respective p values, see table <ref type="table" target="#tab_3">4</ref>. The frequency of the Â4 allele was highest in the ACT AT genotype in s-IBM patients, whereas in the controls similar Â4 counts were shown in the different ACT genotypes. The former differences are not statistically significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>This study was performed to examine the distribution of ApoE and ACT genotypes and its possible relation to disease onset in s-IBM patients.</p><p>Various studies pointed to an ApoE-Â4-allele-associated risk of the development of late onset and sporadic AD <ref type="bibr" target="#b30">[31]</ref>. Moreover, the ACT AA genotype was found to confer an additional genetic risk of developing AD in a smaller number of studies. However, this finding was questioned in further studies <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>. In sporadic and late-onset familial forms of AD, an increased frequency of the ApoE 4 allele is associated with earlier disease onset. In s-IBM patients, Garlepp et al. <ref type="bibr" target="#b20">[21]</ref> suggested that the ApoE Â4 allele modifies the risk of developing s-IBM. Some others denied this hypothesis <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</p><p>We investigated the possible relationship between the ApoE alleles and s-IBM. The results of our study failed to confirm the findings of Garlepp et al. <ref type="bibr" target="#b20">[21]</ref> and are consistent with the results of other groups <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>. There was no correlation between any ApoE polymorphism and an increased or decreased risk of suffering from s-IBM.</p><p>Because of the absence of ApoE mRNA in acute s-IBM affected muscle but not in regenerating muscle, it has been postulated that ApoE reaches the muscle fibres via their low-density lipoprotein receptors <ref type="bibr" target="#b13">[14]</ref>. It is likely that ApoE is intracellularly captured by Aß and any ßpleated amyloid <ref type="bibr" target="#b33">[34]</ref>.</p><p>As similar pathogenic pathways of AD and s-IBM are currently discussed, the results of Yang et al. <ref type="bibr" target="#b34">[35]</ref> are of interest. They found the ApoE Â4 associated with AD risk to be modified by ACT polymorphisms. Testing this association for s-IBM patients we did not find differences in the disease risk and age at disease onset between different ApoE polymorphism carriers depending on the ACT genotype.</p><p>So far, little is known regarding the mechanisms preceding and leading to the formation of the inclusion bodies in s-IBM muscle. Nevertheless, there are some indications that the protein aggregation leading to the formation of inclusions is caused by binding of partially un-or misfolded polypeptides <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref>. Several factors like oxidative stress or aging may lead to this protein un-or misfolding <ref type="bibr" target="#b38">[39,</ref><ref type="bibr" target="#b39">40]</ref>. Hypothetically unknown factors that may lead to ß-amyloid precursor protein overexpression in s-IBM muscle can serve as the underlying process <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b41">42]</ref>.</p><p>ß-Amyloid precursor protein overexpression induces oxidative stress with the formation of free radicals. As a direct consequence of oxidative stress, cyclooxygenase activity is decreased, and several other factors are increased (e.g. glutathione peroxidase, catalase, nitrotyrosine) <ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref>. Simultaneously mitochondria are disturbed, leading to mitochondrial abnormalities <ref type="bibr" target="#b45">[46]</ref>. Ad-ditionally, the oxidative stress may be responsible for the appearance of vacuolated fibres accompanied by congophilia and the accumulation of neurodegeneration-related proteins (ApoE, • 1 -ACT, phosphorylated tau, ubiquitin, presenilin 1, paired helical filaments) <ref type="bibr" target="#b46">[47]</ref>.</p><p>s-IBM shares biochemical features with AD, including ApoE and ß-amyloid peptide immunoreactivity in affected tissues. In AD, a functional pathogenic role has been suggested for ApoE due to its localization near the disease-defining pathological lesions. Interactions between certain proteins found in neurodegenerative diseases (like ApoE and ACT) and molecular chaperones have been suggested <ref type="bibr" target="#b47">[48,</ref><ref type="bibr" target="#b48">49]</ref>. These could serve as nucleating agents in forming amyloid conglomerates. In this respect, the observation that ApoE and ACT genotypes in s-IBM patients do not differ from those of normal controls suggests the accumulation of these proteins in eosinophilic inclusions of affected muscle as an epiphenomenon.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc>Fig. 1. The CfO-digested ApoE amplicons (exon 4 partly, including codon 112 and 158) with an 83-bp band indicating the Â2 allele, a 91-bp band for the Â3 allele and a 72-bp band corresponding to the Â4 allele.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>ApoE genotype and allele frequencies</figDesc><table><row><cell></cell><cell>Control</cell><cell>s-IBM</cell><cell>p value</cell></row><row><cell></cell><cell>group</cell><cell>patients</cell><cell>Mantel-Haenszel</cell></row><row><cell></cell><cell>(n = 57)</cell><cell>(n = 35)</cell><cell>corrected</cell></row><row><cell>ApoE genotype</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Â2/3</cell><cell>4 (7)</cell><cell>5 (14.2)</cell><cell>F: 0.29</cell></row><row><cell>Â2/4</cell><cell>0</cell><cell>2 (5.7)</cell><cell>F: 0.14</cell></row><row><cell>Â3/3</cell><cell>41 (72)</cell><cell>20 (57.1)</cell><cell>0.15</cell></row><row><cell>Â3/4</cell><cell>9 (15.8)</cell><cell>8 (22.8)</cell><cell>0.3</cell></row><row><cell>Â4/4</cell><cell>2 (3.5)</cell><cell>0</cell><cell>F: 0.52</cell></row><row><cell cols="2">ApoE allele frequency</cell><cell></cell><cell></cell></row><row><cell>Â2</cell><cell>0.035</cell><cell>0.1</cell><cell>F: 0.19</cell></row><row><cell>Â3</cell><cell>0.833</cell><cell>0.757</cell><cell>0.25</cell></row><row><cell>Â4</cell><cell>0.114</cell><cell>0.143</cell><cell>F: 0.76</cell></row><row><cell cols="4">Genotype results are numbers, with percentages in parentheses;</cell></row><row><cell cols="2">F = two-tailed Fisher's exact test.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc>Published results of ApoE allele frequencies in s-IBM</figDesc><table><row><cell></cell><cell cols="2">n (allele) Â2</cell><cell>Â3</cell><cell>Â4</cell></row><row><cell>Garlepp et al. [21]</cell><cell>28</cell><cell>0.07</cell><cell>0.69</cell><cell>0.29</cell></row><row><cell>Harrington et al. [22]</cell><cell>22</cell><cell>0</cell><cell>0.818</cell><cell>0.182</cell></row><row><cell>Askanas et al. [23]</cell><cell>22</cell><cell>0.09</cell><cell>0.86</cell><cell>0.05</cell></row><row><cell>Own results (2004)</cell><cell>70</cell><cell>0.1</cell><cell>0.757</cell><cell>0.143</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc>ACT genotype and allele frequencies</figDesc><table><row><cell></cell><cell>Control</cell><cell>s-IBM</cell><cell>p value</cell></row><row><cell></cell><cell>group</cell><cell>patients</cell><cell>Mantel-Haenszel</cell></row><row><cell></cell><cell>(n = 57)</cell><cell>(n = 29)</cell><cell>corrected</cell></row><row><cell>ACT genotype</cell><cell></cell><cell></cell><cell></cell></row><row><cell>AA</cell><cell>13 (22.8)</cell><cell>7 (24.1)</cell><cell>0.89</cell></row><row><cell>AT</cell><cell>32 (56.1)</cell><cell>17 (58.6)</cell><cell>0.83</cell></row><row><cell>TT</cell><cell>12 (21.1)</cell><cell>5 (17.3)</cell><cell>0.68</cell></row><row><cell cols="2">ACT allele frequency</cell><cell></cell><cell></cell></row><row><cell>ACT*A</cell><cell>0.509</cell><cell>0.534</cell><cell>0.75</cell></row><row><cell>ACT*T</cell><cell>0.491</cell><cell>0.466</cell><cell>0.75</cell></row><row><cell cols="4">Group results are numbers, with percentages in parentheses.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc>ApoE allele frequencies among the three ACT genotypes</figDesc><table><row><cell cols="2">ApoE alleles</cell><cell cols="2">Control group</cell><cell></cell><cell></cell><cell cols="2">s-IBM patient group</cell><cell></cell></row><row><cell></cell><cell></cell><cell>AA</cell><cell>AT</cell><cell>TT</cell><cell>p value</cell><cell>AA</cell><cell>AT</cell><cell>TT</cell><cell>p value</cell></row><row><cell></cell><cell></cell><cell>(n = 13)</cell><cell>(n = 32)</cell><cell>(n = 12)</cell><cell>Mantel-Haenszel</cell><cell>(n = 7)</cell><cell>(n = 17)</cell><cell>(n = 5)</cell><cell>Mantel-Haenszel</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>corrected</cell><cell></cell><cell></cell><cell></cell><cell>corrected</cell></row><row><cell>Â2</cell><cell></cell><cell>0.038</cell><cell>0.063</cell><cell>0.042</cell><cell>AA/Â2 1</cell><cell>0.143</cell><cell>0.058</cell><cell>0</cell><cell>AA/AT 2</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>F: 0.28</cell><cell></cell><cell></cell><cell></cell><cell>F: 0.57</cell></row><row><cell>Â3</cell><cell></cell><cell>0.846</cell><cell>0.859</cell><cell>0.833</cell><cell></cell><cell>0.785</cell><cell>0.764</cell><cell>0.9</cell></row><row><cell>Â4</cell><cell></cell><cell>0.116</cell><cell>0.078</cell><cell>0.125</cell><cell>AA/Â4 1</cell><cell>0.072</cell><cell>0.178</cell><cell>0.1</cell><cell>AA/AT 2</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>F: 1.0</cell><cell></cell><cell></cell><cell></cell><cell>F: 0.66</cell></row><row><cell>1</cell><cell cols="2">Controls versus patients.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2</cell><cell cols="2">Patients versus patients.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">cant differences in the AA genotype between s-IBM pa-</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">tients and controls. The ACT AA genotype was present in</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">24.1% of patients and 22.8% of controls (p = 0.891). The</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">ACT*A allele was present in 53.4% of patients and 50.9%</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">of the controls (p = 0.750). 17.3% of s-IBM patients exhib-</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">ited the ACT TT phenotype corresponding to 21.1% in</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">control subjects. The ACT*T allele frequency among pa-</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="6">tients (46.6%) and controls (49.1%) did not show a clear</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">difference.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">Eur Neurol 2004;51:215-220</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Inclusion body myositis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Yunis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Samaha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="240" to="248" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">New advances in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="732" to="741" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Sporadic inclusionbody myositis and hereditary inclusion-body myopathies: Current concepts of diagnosis and pathogenesis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="530" to="542" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="486" to="496" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Inflammatory myopathy causing pharyngeal dysphagia: A new entity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Degirolami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Goyal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Otol Rhinol Laryngol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="331" to="335" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="389" to="405" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Newest pathogenetic considerations in inclusion-body myositis: Possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="427" to="433" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prion protein is abnormally accumulated in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leclerc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="25" to="28" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Leclerc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tome</forename><forename type="middle">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="111" to="114" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Use of anti-neurofilament antibody to identify paired-helical filaments in inclusionbody myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="389" to="391" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Boyles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Pitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Mahley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1501" to="1513" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A role for apolipoprotein E, apolipoprotein A-I, and low-density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Boyles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Zoellner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Kosik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Pitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Weisgrab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Mahley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Gebicke-Haerter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ignatius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1015" to="1031" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion-body myositis and myopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Weisgraber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="864" to="872" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">The molecular and genetic basis of AD: The end of the beginning. The 2000 Wartenberg lecture</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="2045" to="2054" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Brewer</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Potter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="92" to="94" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Binding of human apolipoprotein E to synthetic amyloid ß peptide: Isoform-specific effects and implications for late-onset Alzheimer disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Weisgraber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="8098" to="8102" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Roses AD: Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmechel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pericak-Vance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Salvesen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="1977" to="1981" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmechel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">George</forename><forename type="middle">-</forename><surname>Hyslop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Pericak-Vance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Joo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Rosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Gusella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Crapper-Mac-Lach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1467" to="1472" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer&apos;s disease</title>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Med</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="387" to="400" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Apolipoprotein E epsilon 4 in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tabarias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Van Bockxmeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Laing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="957" to="959" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>Downloaded by: University of Illinois 130.126.143.77 -3/9/2023 2:21:00 AM Gossrau</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="page" from="35" to="38" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Apolipoprotein E alleles in sporadic inclusionbody myositis and hereditary inclusion-body myopathy</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Enkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Weisgraber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Roses</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="264" to="265" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Molecular evolution of serpins: Homologous structure of the human alpha 1-antichymotrypsin and alpha 1-antitrypsin gene</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Sifers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Kidd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Ledley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Woo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="7755" to="7759" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Distribution pattern and functional state of alpha 1-antichymotrypsin in plaques and vascular amyloid in Alzheimer&apos;s disease: An immunohistochemical study with monoclonal antibodies against native and inactivated alpha 1-antichymotrypsin</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Rozemuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Abbink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Kamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Stam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Hack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Eikelen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="200" to="207" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis: Newest concepts of pathogenesis and relation to aging and Alzheimer disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism in the Greek population</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sklavounou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Economou-Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karadima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Panas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Avramopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Varsou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vassilopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Petersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Genet</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="216" to="218" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Apolipoprotein E genotype and Lewy body disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Lippa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Crook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pulaski-Salo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hardy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Roses</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dickson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="97" to="103" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Tanzi RE: Apolipoprotein E, survival in Alzheimer&apos;s disease patients and the competing risks of death and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Corder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Strittmatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Schmechel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gaskell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Rimmler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Locke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Conneally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Schmader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1323" to="1328" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Apolipoprotein E polymorphism and susceptibility to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Kamboh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Biol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="195" to="215" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Relationship between serum alpha 1-antichymotrypsin and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Hinds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Kukull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Van Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Schellenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Villacres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Larson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="21" to="27" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Gene polymorphism affecting alpha 1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer&apos;s disease risk</title>
		<author>
			<persName><forename type="first">F</forename><surname>Licastro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pedrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ferri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="388" to="391" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Ultrastructural studies of the cells forming amyloid in the vessel wall in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Wisniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wegiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="117" to="127" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">DeKosky ST: APOE*4-associated Alzheimer&apos;s disease risk is modified by alpha 1-antichymotrypsin polymorphism</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Kamboh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Sanghera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Ferrel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="486" to="488" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Increase of nitric oxide syntheses and nitrotyrosine in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="153" to="158" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Hassles with taking out the garbage: Aggravating aggresomes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Garcia-Mata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sztul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Traffic</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="388" to="396" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Protein aggregation and the ubiquitin proteasome pathway: Gaining the UPPer hand on neurodegeneration</title>
		<author>
			<persName><forename type="first">Shoesmith</forename><surname>Berke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Paulson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Genet Dev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="253" to="261" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">A role of molecular chaperones in inclusion body formation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Carrio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villaverde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FEBS Lett</title>
		<imprint>
			<biblScope unit="volume">537</biblScope>
			<biblScope unit="page" from="215" to="221" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="15" to="32" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Danger: Misfolding proteins</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tjt</forename><surname>Pinheiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">416</biblScope>
			<biblScope unit="page" from="483" to="484" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Strong immunoreactivity of alpha 1-antichymotrypsin colocalizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusionbody myositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="378" to="382" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Inclusion-body myositis and myopathies: Different etiologies, possibly similar pathogenic mechanisms</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="525" to="531" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer&apos;s disease? Clue from inclusion-body myositis, cultured human muscle, and transgenic mice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1673" to="1677" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1089" to="1097" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion-body myositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Molnar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biochem</title>
		<imprint>
			<biblScope unit="volume">174</biblScope>
			<biblScope unit="page" from="277" to="281" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<author>
			<persName><forename type="first">J</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cervenkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Estupian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Vnencak-Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Gajdusek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Korczyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Goldfarb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">APOE in non-Alzheimer amyloidoses: Transmissible spongiform encephalopathies</title>
				<imprint>
			<date type="published" when="1998">1998</date>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="548" to="553" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Chaperoning brain diseases</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gambetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">392</biblScope>
			<biblScope unit="page" from="23" to="24" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Fourteen newly recognized proteins at the human neuromuscular junctions and their nonjunctional accumulation in inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">841</biblScope>
			<biblScope unit="page" from="28" to="56" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
